TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01670734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous
Study: NCT04045132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media-Based Parenting Program
Description: Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MoodGym
Description: Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MoodGym
Description: Participants in the control group will be enrolled in MoodGym, an evidence-based online Cognitive Behavioral Therapy (CBT) program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
Study: NCT03219606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organized education course of Modified Rodnan Skin Scoring
Description: 1. Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~2. Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~3. Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course.
Study: NCT04108494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of omentectomy
Description: Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
Study: NCT02835950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Intra-Vascular UltraSound (TIVUS™) System
Description: The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation.
Study: NCT01152359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice
Description: Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
Study: NCT01230424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: 40 mg into the study knee joint every 12 weeks for a total of 8 injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection as Placebo
Description: Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
Study: NCT04476407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benapenem
Description: single-dose Benapenem 1.0mg(iv), 60min infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benapenem
Description: single-dose Benapenem 1.0mg(iv), 60min infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: benapenem
Description: single-dose Benapenem 1.0mg(iv), 60min infusion
Study: NCT03887507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta Therapy
Description: Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Program
Description: The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
Study: NCT00546117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lansoprazole
Description: Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing \>30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Solutab in 15 and 30 mg dosages.
Study: NCT02012738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FORNET
Description: 8 individual sessions:~* 1 lifeline~* 6 exposure sessions~* 1 outlook

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: 7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control Group (camp)
Description: Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting List Control Group (no camp)
Description: Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
Study: NCT02339129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SST-0225
Description: SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
Study: NCT02017912

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurown MSC-NTF cells
Description: Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipient administration by combined intramuscular and intrathecal administration
Study: NCT01770366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight and Exercise Lifestyle Support (WELS)
Description: Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT00742508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK&F-105517-D 10 mg capsule
Description: 1 capsule once a day

Intervention type: DRUG
Group type: OTHER
Intervention: Carvedilol-immediate release (IR) 2.5 mg tablet
Description: 1 or 2 tablet(s) twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK&F-105517-D 20 mg capsule
Description: 1 capsule once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK&F-105517-D 40 mg capsule
Description: 1 or 2 capsule(s) once a day

Intervention type: DRUG
Group type: OTHER
Intervention: Carvedilol-IR 10 mg tablet
Description: 1 tablet twice a day
Study: NCT04606823

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive surgery
Description: The subjects will be implanted with a bone anchored hearing system using a minimally invasive surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Glasgow Benefit Inventory (GBI)
Description: A quality of life-questionnaire is to be completed by the subjects at one occasion.

Intervention type: OTHER
Group type: OTHER
Intervention: Additional follow-up visits after surgery
Description: There are 1-3 additional follow-up visits after surgery (compared to the routine clinical practice of the surgeons/clinics).
Study: NCT00352053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Description: Tenofovir DF 300-mg tablet, administered orally, daily + OBR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tenofovir DF Placebo administered orally, daily + OBR
Study: NCT00735293

Intervention type: DEVICE
Group type: OTHER
Intervention: VASER
Description: A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
Study: NCT03900143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tightra vaginal device
Description: Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
Study: NCT01001780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin; Cyclophosphamide; Rituximab
Description: Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
Study: NCT02583568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: three days prior to surgery bevacizumab-800CW will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-800CW
Description: three days prior to surgery bevacizumab-800CW will be administered
Study: NCT03601104

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity eccentric training
Description: High intensity eccentric training group with 80% of isometric peak torque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity eccentric training with BFR
Description: Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity eccentric training with BFR
Description: Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity eccentric training
Description: Low intensity eccentric training group with 40% of isometric peak torque
Study: NCT01003184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide once weekly
Description: subcutaneous injection, 2mg, once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
Study: NCT04657549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Tonsillectomy is done by monopolar electrocautery, bipolar scissors or cold instruments. First the mucosa of the anterior palatinal arch is incised and tonsillar capsule identified, then tonsillar tissue is removed along the capsule. Any bleeding is coagulated either with monopolar or bipolar electrocautery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillotomy
Description: Tonsillotomy is done using monopolar electrosurgery, bipolar scissors or coblator device. Most of the tonsillar tissue is removed, exceeding the removal behind the line between anterior and posterior palatinal arch so that only thin layer of tonsil tissue is left over the tonsillar capsule.
Study: NCT00557622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00227760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01578096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stress management
Description: The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
Study: NCT04005937

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H-reflex
Description: Electrical stimulation of Group Ia afferent of muscle spindle
Study: NCT00000143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant and oral ganciclovir
Description: oral ganciclovir, 1 gm three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir intravenous
Description: intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
Study: NCT03013686

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interval appendectomy
Description: Laparoscopic appendectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up with MRI
Description: Abdominal MRI
Study: NCT02803320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 50 Y65 110 (BAY 987516)
Description: Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
Study: NCT00874289

Intervention type: OTHER
Intervention: NGAL kit
Description: Kit to test NGAL levels in heart failure patients

Intervention type: OTHER
Intervention: NGAL kit
Description: Kit to test NGAL levels in heart failure patients
Study: NCT04503538

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine visit
Description: Participants will be provided with a Wifi-and cellular enabled electronic tablet. Additionally, participants will receive a kit that contains a thermometer, a blood pressure monitoring cuff, and a pulse oximeter (to measure oxygen saturation level). Participants will attend an educational session to learn how the telemedicine visit works. Caregivers should attend with participants and will be trained to take temperatures, blood pressures, and oxygen saturation levels. Participants will also be asked to complete a test telehealth visit.
Study: NCT03802162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-355A (D797/Memantine HCl 20mg)
Description: once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-355B (D797/Memantine HCl 20mg)
Description: once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D797
Description: once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D324 (Memantine HCl 10mg)
Description: twice a day
Study: NCT03662997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bordered Five-Layer Foam Dressing
Description: Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bordered Five-Layer Foam Dressing
Description: Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bordered Five-Layer Foam Dressing
Description: Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bordered Five-Layer Foam Dressing
Description: Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydropolymer Foam Dressing
Description: Hydropolymer, adhesive foam island dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydropolymer Foam Dressing
Description: Hydropolymer, adhesive foam island dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocellular Multi-Layer Foam Dressing
Description: Multi-layered, hydrocellular foam dressing with silicone adhesive

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocellular Multi-Layer Foam Dressing
Description: Multi-layered, hydrocellular foam dressing with silicone adhesive
Study: NCT01865617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Description: Given IV
Study: NCT01430780

Intervention type: DRUG
Intervention: nitrate group
Description: Isosorbide Mononitrate orally 20mg twice per day.

Intervention type: DRUG
Intervention: control group
Description: placebo
Study: NCT01873300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Esophageal Myotomy
Description: Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
Study: NCT02522013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Study: NCT04282291

Intervention type: PROCEDURE
Intervention: fascial block as postoperative analgesia
Description: The tissue damage induced by the surgery generates a nociceptive pain which is accompanied by inflammatory mechanism (somatic pain), visceral and neuropathic pain, and why the treatment must be adapted to each surgical procedure. As the innervation of the upper abdominal wall depends mainly on the last intercostal nerves, the block of these nerves should be considered a good analgesic strategy to avoid the somatic pain. The placement of the local anesthetic in the serratus intercostal plane at the eighth rib (serratus intercostal plane block, SIPB) in the middle axillary line, managed to block the lateral and anterior cutaneous branches of the last intercostal nerves (T7-11). The results were satisfactory in the postoperative pain control of the patients with open cholecystectomy.

Intervention type: DRUG
Intervention: Morphine
Description: The continuous (basal) dose

Intervention type: DEVICE
Intervention: PCA CADD Smith Medical pumps
Description: perfusion

Intervention type: DEVICE
Intervention: PCA CADD Smith Medical pumps
Description: perfusion
Study: NCT01854879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 6 sound processor
Study: NCT03721042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: olfactory measuring device
Description: Patients blowing into bags then analysis by olfadiag system
Study: NCT01846221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.